Opdualag 240 mg/80 mg concentrate for solution for infusion | Concentrate for solution for infusion | Bristol-Myers Squibb Pharma EEIG

Company:
Bristol-Myers Squibb Pharma EEIG
Status:
New
Legal Category:
Product subject to medical prescription which may be renewed (B)
Active Ingredient(s):
Nivolumab
This medicinal product is subject to additional monitoring.
*Additional information is available within the SPC or upon request to the company

What is a Patient Information Leaflet and why is it useful?
A Patient Information Leaflet (PIL) is the leaflet for patients containing information on taking a medicine, that is included with the medicine packaging. It is written by pharmaceutical companies as a patient version of the Summary of Product Characteristics (SPC). Changes to the PIL after your medicine was packed may mean that the version on medicines.ie may differ from the version found with your medicine. You can compare the “Leaflet prepared or revised date” towards the end of the leaflet in the pack with the version that is on the website to find out if there have been any changes to the information since your medicine was packed.

Opdualag 240 mg/80 mg concentrate for solution for infusion * Pharmacy Only: Prescription